Takeda and Zuellig Pharma Partner to Expand Medicine Access Across Three Southeast Asian Markets

17 November 2026 | Tuesday | News


Effective 1 December 2026, Zuellig Pharma will support commercialisation and distribution of selected Takeda medicines in Malaysia, Indonesia and the Philippines.

Takeda and Zuellig Pharma announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutions across Malaysia, Indonesia and the Philippines. Effective December 1, 2026, the collaboration will bring together selected products from Takeda's innovative portfolio with Zuellig Pharma's extensive regional network, commercial capabilities and deep local market expertise, to strengthen sustainable access to medicines and improve health outcomes across the region.

Building on the long-standing relationship between the two companies, the collaboration combines complementary capabilities to support patients, healthcare professionals and healthcare systems across the three countries, with Zuellig Pharma supporting the end-to-end commercialization as well as distribution of selected Takeda products in the markets.

Takeda remains committed to serving patients, healthcare professionals and communities across Malaysia, Indonesia and the Philippines through its continued direct management of key portfolios and its new strategic regional collaboration with Zuellig Pharma. Takeda will continue to directly manage its vaccines portfolio across all three countries. In Indonesia, its locally manufactured medicine through the PT Takeda Indonesia (PTTI) joint venture and plasma-derived therapies portfolio will also remain under Takeda’s direct management, supporting continued access and care for patients. Together, these activities reflect Takeda's ongoing commitment to addressing public health needs, supporting specialized patient care, and expanding access to innovative medicines across Malaysia, Indonesia and the Philippines.

“At Takeda, we are focused on delivering innovative medicines to the patients who need them most,” said Dion Warren, General Manager, Managed Markets, International Business Unit, Takeda. “By combining our innovative portfolio with Zuellig Pharma’s extensive healthcare network and deep expertise across Asia, we can strengthen our ability to serve patients across Southeast Asia and support sustainable access to healthcare. This collaboration reflects our long-term commitment to the region and the communities we serve,”

“Ensuring timely and reliable access to medicines requires a shared commitment to addressing patients’ evolving healthcare needs,” said John Graham, Group CEO, Zuellig Pharma. “We are pleased to deepen our collaboration with Takeda and support its mission of bringing innovative therapies to patients across the region. We value the trust Takeda has placed in us and remain committed to leveraging our regional network, local market expertise and healthcare capabilities to strengthen access to quality healthcare and improve patient outcomes across Asia,”

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close